Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells Minhong TangJohn CrownMichael J Duffy Research Open access 26 May 2023 Pages: 541 - 550
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma Elizabeth I. BuchbinderAnita Giobbie-HurderPatrick A. Ott Research 29 May 2023 Pages: 551 - 555
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma Yongzhao LiQidong YangGuoyan Qi Research 15 June 2023 Pages: 556 - 563
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma Hanwen LuBingchang ZhangZhanxiang Wang Research 16 June 2023 Pages: 564 - 578
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study Xue WangJinxiang HuangJian Liu Research 27 June 2023 Pages: 579 - 586
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells Ibtehal MohammedAli Haider AlhammerInam Sameh Arif Research 04 July 2023 Pages: 587 - 595
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates Özkan YalkinogluAndreas BeckerRainer Strotmann Research Open access 06 July 2023 Pages: 596 - 605
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma Yuqin SongKeshu ZhouJun Zhu Research Open access 08 July 2023 Pages: 606 - 616
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study Chenghao ZhaoHuzheng YanMingsheng Huang Research 12 July 2023 Pages: 617 - 626
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma Guihong LiuYachun LuMing Chen Correction 27 May 2023 Pages: 627 - 628